Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32)

Journal of Diabetes Investigation

Volumn 5, Issue 5, 2014, Pages 581-587

  Oishi, Mariko ^a   Yamazaki, Katsuya ^b   Okuguchi, Fuminobu ^c   Sugimoto, Hidekatsu ^d   Kanatsuka, Azuma ^e   Kashiwagi, Atsunori ^f  

^a Oishi Clinic   (Japan)

^b Kawai Clinic   (Japan)

^c Okuguchi Clinic   (Japan)

^d Sugimoto Clinic   (Japan)

^e Chiba Central Medical Center   (Japan)

^f SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Glycemic control; Oral antidiabetic drugs; Type 2 diabetes mellitus

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BODY MASS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET THERAPY; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; RETROSPECTIVE STUDY; TREND STUDY;

EID: 84908565650     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12183     Document Type: Article

References (29)

1. The Diabetes Control and Complications Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin- dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. Ohkubo Y, Kishihata H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk if complications in patients with type 2 diabetes (UKPDS33). Lancet 1998; 352: 837-853.
4. Kobayashi M, Yamazaki K, Hirao K, et al. The status of diabetes control and anti-diabetic drug therapy in Japan - a cross-sectional survey of 17, 000 patients with diabetes mellitus (JDDM1). Diabetes Res Clin Pract 2006; 73: 198-204.
5. Kanatsuka A, Kawai K, Hirao K, et al. Research on antihyperglycemic therapies in patients with type 2 diabetes mellitus in Japan (I): drug therapies and actual drug use. J Jpn Diabetes Soc 2006; 49: 409-415 (Japanese).
6. Kanatsuka A, Kawai K, Hirao K, et al. Research on antihyperglycemic therapies in patients with type 2 diabetes mellitus in Japan (II): the effectiveness on glycemic control (JDDM7). J Jpn Diabetes Soc 2006; 49: 919-927 (Japanese).
7. Seino Y, Nanjo K, Tajima N, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
8. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan diabetes society to national glycohemoglobin in standardization program values. J Diabetes Invest 2012; 3: 39-40.
9. Walley T, Hughes D, Kendall H. Trends and influences on use of antidiabetic drugs in England, 1992-2003. Pharmacoepidemiol Drug Saf 2005; 14: 769-773.
10. Filion KB, Joseph L, Boivin JF, et al. Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. Pharmacoepidemiol Drug Saf 2009; 18: 973-976.
11. Mazzaglia G, Yurgin N, Boye KS, et al. Prevalence and antihyperglycemic prescribing trends for patients with type 2 diabetes in Italy: a 4-year retrospective study from national primary care data. Pharmacol Res 2008; 57: 358-363.
12. Baviera M, Monesi L, Marzona I, et al. Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombarsy Region: a large population-based study. Diabetes Res Clin Pract 2011; 93: 123-130.
13. Boyc KS, Yurgin N, Lage M. Trends in the prescription of antidiabetic medications in France: evidence from primary care physicians. Adv Ther 2007; 24: 803-813.
14. Chiang CW, Chiu HF, Chen CY, et al. Trends in the use of oral antidiabetic drugs by outpatients in Taiwan: 1997-2003. J Clin Pharm Ther 2006; 31: 73-82.
15. Cohen FJ, Conklin J, Neslusan CA, et al. Recent antihyperglycemic prescribing trends for U.S. privately insured patients with type 2 diabetes. Diabetes Care 2003; 26: 1847-1851.
16. Boccuzzi SJ, Sung JCY, Wogen J, et al. Utilization of oral hyperglycemic agents in a drug-insured U.S. population. Diabetes Care 2001; 24: 1411-1415.
17. UK Prospective Diabetes Study Group (UKPDS28). A randomized trial of efficacy of early addition of metformin in sulphonylurea-treated type 2 diabetes. Diabetes Care 1998; 21: 87-92.
18. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). Lancet 1998; 352: 854-865.
19. The DECODE-study group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 1999; 42: 647-654.
20. Qiao Q, Nakagami T, Tuomilehto J, et al.; International Diabetes Epidemiology Group; DECODA Study Group. Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia 2000; 43: 1470-1475.
21. Yoshiike N, Seino F, Tajima S, et al. Twenty-year changes in the prevalence of overweight in Japanese adults: the National Nutrition Survey 1976-1995. Obes Rev 2002; 3: 183-190.
22. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting; systematic review and meta-analysis. BMJ 2012; 344: e1369. doi:10.1136/bmj.e1369.
23. Inaba W, Mizukami H, Kamata K, et al. Effect of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats. Eur J Pharmacol 2012; 691: 297-306.
24. Sato K, Nakamura A, Shirakawa J, et al. Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and β-cell function and mass in insulin receptor substrate-2-knock-out mice fed a high-fat diet. Endocrinology 2012; 153: 1093-1102.
25. Alexander CG, Sehgal NL, Moloney RM, et al. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008; 168: 2088-2094.
26. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a Patient-Centered Approach, Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
27. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS49). UK Prospective Diabetes Study (UKPDS) group. JAMA 1999; 281: 2005-2012.
28. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. Scientific review. JAMA 2002; 287: 360-372.
29. Kimmel B, Inzucchi SE. Oral agents for type 2 diabetes: an update. Clin Diabetes 2005; 23: 64-76.